From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of RapamycinHIDALGO, Manuel.Journal of clinical oncology. 2012, Vol 30, Num 1, pp 85-87, issn 0732-183X, 3 p.Article

Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine TumorsZHI RONG QIAN; TER-MINASSIAN, Monica; XIHONG LIN et al.Journal of clinical oncology. 2013, Vol 31, Num 27, pp 3418-3425, issn 0732-183X, 8 p.Article

Spatial Coupling of mTOR and Autophagy Augments Secretory PhenotypesNARITA, Masako; YOUNG, Andrew R. J; TAVARE, Simon et al.Science (Washington, D.C.). 2011, Vol 332, Num 6032, pp 966-970, issn 0036-8075, 5 p.Article

Temsirolimus, an Inhibitor of Mammalian Target of RapamycinRINI, Brian I.Clinical cancer research. 2008, Vol 14, Num 5, pp 1286-1290, issn 1078-0432, 5 p.Article

Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and AutophagyQUIDVILLE, Virginie; ALSAFADI, Samar; DELALOGE, Suzette et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 7, pp 2247-2258, issn 0008-5472, 12 p.Article

Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-βRAHIMI, Rod A; ANDRIANIFAHANANA, Mahefatiana; WILKES, Mark C et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 1, pp 84-93, issn 0008-5472, 10 p.Article

TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser²⁴⁸¹ Is a Marker for Intact mTOR Signaling Complex 2COPY, Jeremy; MANNING, Gerard; HUNTER, Tony et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 5, pp 1821-1827, issn 0008-5472, 7 p.Article

Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR InhibitionHAE YUN NAM; MYUNG WOUL HAN; HYESUNG JEON et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 14, pp 4267-4277, issn 0008-5472, 11 p.Article

Lactate Dehydrogenase B Is Critical for Hyperactive mTOR-Mediated TumorigenesisXIAOJUN ZHA; FANG WANG; YING WANG et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 1, pp 13-18, issn 0008-5472, 6 p.Article

Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor ComplexBEEVERS, Christopher S; LONG CHEN; LEI LIU et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 3, pp 1000-1008, issn 0008-5472, 9 p.Article

Inhibitors of the Mammalian Target of Rapamycin and Transplant ToleranceBESTARD, Oriol; CRUZADO, Josep M; GRINYO, Josep M et al.Transplantation. 2009, Vol 87, Num 8S, issn 0041-1337, S27-S29, SUPArticle

Dysregulation of mTOR Signaling in Neuropsychiatric Disorders: Therapeutic ImplicationsSAWICKA, Kirsty; SUZANNE ZUKIN, R.Neuropsychopharmacology (New York, NY). 2012, Vol 37, Num 1, pp 305-306, issn 0893-133X, 2 p.Article

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody productionSHULING ZHANG; READINGER, Julie A; PARENT, Carole A et al.Blood. 2011, Vol 117, Num 4, pp 1228-1238, issn 0006-4971, 11 p.Article

Negative regulation of mTOR activation by diacylglycerol kinasesGORENTLA, Balachandra K; WAN, Chi-Keung; ZHONG, Xiao-Ping et al.Blood. 2011, Vol 117, Num 15, pp 4022-4031, issn 0006-4971, 10 p.Article

Transcriptional Control of Cellular Metabolism by mTOR SignalingYECIES, Jessica L; MANNING, Brendan D.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 8, pp 2815-2820, issn 0008-5472, 6 p.Article

Exploiting Tumor Vulnerabilities: Epigenetics, Cancer Metabolism and the mTOR Pathway in the Era of Personalized MedicineMUNOZ-PINEDO, Cristina; GONZALEZ-SUAREZ, Eva; PORTELA, Anna et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 14, pp 4185-4189, issn 0008-5472, 5 p.Article

MTOR-What Does It Do?HALL, M. N.Transplantation proceedings. 2008, Vol 40, Num 10, issn 0041-1345, S5-S8, SUPConference Paper

Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cellsWEICHHART, Thomas; HAIDINGER, Michael; HÖRL, Walter H et al.Blood. 2011, Vol 117, Num 16, pp 4273-4283, issn 0006-4971, 11 p.Article

Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 alphaMCLNTURFF, Alison M; CODY, Mark J; ELLIOTT, Elizabeth A et al.Blood. 2012, Vol 120, Num 15, pp 3118-3125, issn 0006-4971, 8 p.Article

MTOR-Understanding the Clinical EffectsCONTRERAS, A. G; DORMOND, O; EDELBAUER, M et al.Transplantation proceedings. 2008, Vol 40, Num 10, issn 0041-1345, S9-S12, SUPConference Paper

Carcinomes cutanés après transplantation : La peau du transplanté - 2e partie: aspects cancérologiques = Cutaneous carcinomas after organ transplantationEUVRARD, Sylvie.Le Courrier de la transplantation. 2010, Vol 10, Num 2, pp 57-61, issn 1628-8319, 5 p.Article

Foxp3⁺ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR InhibitionYANPING WANG; SPARWASSER, Tim; FIGLIN, Robert et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 8, pp 2217-2228, issn 0008-5472, 12 p.Article

Keloid Disease Can Be Inhibited by Antagonizing Excessive mTOR Signaling With a Novel Dual TORC1/2 InhibitorSYED, Farhatullah; SHERRIS, David; PAUS, Ralf et al.The American journal of pathology. 2012, Vol 181, Num 5, pp 1642-1658, issn 0002-9440, 17 p.Article

Preemptive Use of Mammalian Target of Rapamycin Inhibitors in Living Donor TransplantationVODENIK, B; ROVIRA, J; DIEKMANN, F et al.Transplantation proceedings. 2011, Vol 43, Num 7, pp 2568-2573, issn 0041-1345, 6 p.Article

S6K1 and mTOR regulate Rac1-driven platelet activation and aggregationASLAN, Joseph E; TORMOEN, Garth W; LOREN, Cassandra P et al.Blood. 2011, Vol 118, Num 11, pp 3129-3136, issn 0006-4971, 8 p.Article